HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.

AbstractBACKGROUND:
Irinotecan alone and plus mitomycin C have been proven to be effective as second-line chemotherapy for advanced gastric cancer. The objective of the present study was to compare the efficacy and safety of irinotecan alone (CA) and with mitomycin C (CM) in clinical practice.
PATIENTS AND METHODS:
Between November 2006 and December 2011, 46 patients with advanced gastric cancer refractory to fluoropyrimidine and platinum were treated with CM (n=22) or CA (n=24).
RESULTS:
Baseline characteristics of the patients were similar in the two treatment groups, with the exception of the sex ratio. The median progression-free survival was 3.9 months in the CM arm and 3.7 months in the CA arm (p=0.25), and the median overall survival was 9.6 and 8.7 months (p=0.36), respectively. The overall response rate was 18% in the CA arm and 9% in the CM arm (p=0.38). Grade 3/4 neutropenia (45% vs. 25%), anemia (36% vs. 4%), febrile neutropenia (14% vs. 8%), anorexia (14% vs. 8%) tended to be higher in the CM arm than in the CA arm.
CONCLUSION:
Although the efficacy of CM and CA for advanced gastric cancer refractory to fluoropyrimidine and platinum was not significantly different, CM tended to lead to greater incidence of adverse events in clinical practice.
AuthorsAkira Ueda, Ayumu Hosokawa, Kohei Ogawa, Hiroki Yoshita, Hiroshi Mihara, Takayuki Ando, Shinya Kajiura, Haruka Fujinami, Jun Nishikawa, Masami Minemura, Mitsuhiro Terada, Takashi Kobayashi, Naoki Horikawa, Kazuhisa Yabushita, Masayuki Note, Toshiro Sugiyama
JournalAnticancer research (Anticancer Res) Vol. 33 Issue 11 Pg. 5107-11 (Nov 2013) ISSN: 1791-7530 [Electronic] Greece
PMID24222156 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Platinum
  • Mitomycin
  • Irinotecan
  • Fluorouracil
  • Camptothecin
Topics
  • Adenocarcinoma (drug therapy, mortality, pathology)
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Camptothecin (administration & dosage, analogs & derivatives)
  • Drug Resistance, Neoplasm (drug effects)
  • Female
  • Fluorouracil (administration & dosage)
  • Follow-Up Studies
  • Humans
  • Irinotecan
  • Male
  • Middle Aged
  • Mitomycin (administration & dosage)
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Platinum (administration & dosage)
  • Prognosis
  • Salvage Therapy
  • Stomach Neoplasms (drug therapy, mortality, pathology)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: